ClinicalTrials.gg
RecruitingNCT07211178GEMINI BreastUpdated Sep 3, 2026

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

An observational study in Breast Cancer, TNBC - Triple-Negative Breast Cancer and HR Positive/HER-2 Negative Breast Cancer, sponsored by Tempus AI. Recruiting at 16 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tempus AI · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
6th of 38
900 · median 90
Started
2025
with 46 others
Observational
38 of 645
12 open now
Primary completion
2032-12
later than 254 of 262 live
Registered
607th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 6th largest by planned enrollment of the 38 observational ones that give a count, is one of 47 that started in 2025, is one of 38 observational ones, reaches primary completion later than 254 of the 262 other live ones, and was the 607th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.

A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working.

Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.

03

Conditions studied

  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • HR Positive/HER-2 Negative Breast Cancer
  • HER2 + Breast Cancer
  • Early Stage Breast Cancer

Browse trials for

Keywords

  • Minimal Residual Disease
  • MRD
  • Next generation sequencing
  • NGS
  • ctDNA
  • Early Stage Breast Cancer
  • TNBC - Triple Negative Breast Cancer
  • HR positive / HER-2 negative breast cancer
  • HER2+ breast cancer
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 900 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Tempus AI is the lead sponsor of 14 studies on the registry; 9 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population of this study includes early stage breast cancer patients with triple negative breast cancer (Stages I to III), HER2 positive (Stages II and III), and high risk HR positive HER-2 negative (Stages II and III).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Cohorts:

  1. Willing and able to participate in the research and provide biospecimens
  2. Willing and able to provide
  3. Must be diagnosed with breast cancer

Cohort 1: Treatment Cohort 1A: Newly Diagnosed, High Risk HR+,-

  1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)
  2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.

Cohort 1B: HER2+ 1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease). Inclusive of HR+ or HR- patients.

Cohort 1C: Triple Negative Breast Cancer

1. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease).

Cohort 2: Adjuvant Therapy / Surveillance Cohort 2A: Newly Diagnosed HR+,HER2-

  1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)
  2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.
  3. Have undergone curative intent surgery with no clinical evidence of disease.

Cohort 2B: HER2+

  1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease)
  2. Have undergone curative intent surgery with no clinical evidence of disease.

Cohort 2C: Triple Negative Breast Cancer

  1. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease)
  2. Have undergone curative intent surgery with no clinical evidence of disease.

Cohort 3: 5-Years Post-Diagnosis Surveillance (NED)

  1. A known HR+, HER2- breast cancer treated with curative intent (Stage II to III disease).
  2. No Evidence of Disease (NED) ≥ 5 years from initial diagnosis.
  3. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.

Exclusion criteria

Exclusion Criteria:

  1. Not willing or able to adhere with the study procedures
  2. Active secondary
  3. Diagnosis of a malignancy within 3 years of breast cancer diagnosis Note: Ductal carcinoma in situ (DCIS, ipsilateral or contralateral) within 3 years is not excluded.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 1: Neoadjuvant Therapy

    There are no interventions in this observational study. Cohort 1 includes participants who will receive neoadjuvant treatment prior to surgery.

    Other: There are no interventions in this observational study.

  • Cohort 2: Adjuvant Therapy / Surveillance

    There are no interventions in this observational study. Cohort 2 includes participants who will receive adjuvant therapy after surgery.

    Other: There are no interventions in this observational study.

  • Cohort 3: 5 Years Post-Diagnosis Surveillance

    There are no interventions in this observational study. Cohort 3 includes participants who have no evidence of disease for at least 5 years post diagnosis.

    Other: There are no interventions in this observational study.

Interventions

  • OtherThere are no interventions in this observational study.

    There are no interventions in this observational study.

07

What researchers measure

Primary outcomes

  1. Invasive Disease-Free Survival (iDFS) stratified by MRD status during neoadjuvant, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up

    Time frame: 5 years

Secondary outcomes

  1. Distant disease free survival rates stratified by MRD status during neoadjuvant treatment

    Time frame: 5 years

  2. Overall Survival rates stratified by MRD status during neoadjuvant treatment, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up

    Time frame: 5 years

  3. Pathologic Complete Response (pCR) or Residual Cancer Burden (RCB) rate stratified by MRD status at post-surgery landmark

    Time frame: 5 years

  4. Time from First Positive MRD Sample to Recurrence

    Time frame: 5 years

08

Study locations

16 of 16 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2032, 86 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Oct 7, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2033
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211178
Lead sponsor
Tempus AI
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Oct 27, 2025
Primary completion
Dec 2032 (estimated)
Completion
Dec 2033 (estimated)
Last update
Sep 3, 2026

Study contacts

GEMINI Breast Clinical Study Manager
Contact
gemini-breast@tempus.com
(833) 514-4187
Michelle Ting-Lin, MD
principal investigator · Tempus AI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion